The U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, by Drugs (Lenalidomide, Decitabine, Azacitidine, Luspatercept, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country/Region (U.S., Europe, and China) was valued at US$ 2,042.6 Million in 2020, and is projected to exhibit a CAGR of 7.6% during the forecast period (2020-2027).
The key players are focusing on fund raising to boost research and development of novel therapeutic ways for the treatment of myelodysplastic syndrome (MDS), in order to expand their product portfolio and presence in the market. For instance, in March 2020, Keros Therapeutics, Inc., a biotechnology company headquartered in Massachusetts, United States, announced fund raising of US$ 56 million in Series C financing, bringing its total venture funding to US$ 78.5 million to date. The Series C financing was led by new investors Foresite Capital, OrbiMed, Cowen Healthcare Investments, and Venrock. Certain existing investors of Keros also participated including Pontifax, Arkin Bio Ventures, Partners Innovation Fund, Global Health Sciences Fund, and Medison Pharma.
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has affected various industries globally. The players operating in the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market are facing major challenges on various fronts due to the COVID-19 pandemic. Supply chain and manufacturing activities in China, Italy, Spain, the U.K., and the U.S. have been disrupted due to lockdowns implemented by governments in the past few months, while countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drug products. Moreover, various manufacturing companies are facing shortages of pharmaceutical products used for treatment of various diseases such as blood cancer, MDS, and others due to outbreak of COVID-19 pandemic. For instance, in December 2020, the U.S. Food Drug and Administration announced the shortage of Azacitidine for injection in the U.S. Azacitidine for injection are indicated for the treatment of myelodysplastic syndrome (MDS) and other cancers.
Browse 77 Market Data Tables and 41 Figures spread through 255 Pages and in-depth TOC on “U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market”- Forecast to 2027, U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, by Drugs (Lenalidomide, Decitabine, Azacitidine, Luspatercept, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country/Region (U.S., Europe, and China).
The increasing adoption of inorganic growth strategies such as collaboration by key players is expected to drive growth of the U.S., Europe, and China myelodysplastic syndrome treatment market. For instance, In March 2018, Onconova Therapeutics and Pint Pharma GmbH entered an agreement for commercialization of rigosertib that is used for MDS treatment in Latin America.
Key Takeaways of the U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market:
- The U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market is expected to exhibit a CAGR of 7.6% during the forecast period, owing to increase in research and development of therapeutics for the treatment of myelodysplastic syndrome (MDS). For instance, in March 2018, FibroGen Inc. received approval from China Food and Drug Administration (CFDA) for conducting Phase II/III trial of drug roxadustat in low risk myelodysplastic syndrome patients with anemia.
- Among distribution channel, hospital pharmacies segment in the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market is estimated to be valued at US$ 1,179.4 Million in 2020, and is expected to exhibit a CAGR of 8.0% during the forecast period. Rising hospital admission of myelodysplastic syndrome patients along with increasing geriatric population are expected to favor growth of the segment over the forecast period. For instance, according to the American Society of Hematology report published in 2016, a total of 885,726 patients suffering from myelodysplastic syndrome (MDS) were admitted in hospitals, out of which 803,341 admissions (90.6%) were of patients aged >65 years during 2005 - 2015 in the U.S.
- Major players operating in the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market include Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.
